Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

809
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
809
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

849
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
849
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.1K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.4K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.4K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.4K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.4K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

699
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
699

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphologic evaluation in fibrotic hypersensitivity pneumonitis: the era of quantitative CT is upon us.

Annals of the American Thoracic Society·2026
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026
Same author

Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease.

ERJ open research·2026
Same author

Changes in Interstitial Lung Disease Nomenclature.

Archivos de bronconeumologia·2026
Same author

Response.

Chest·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Mar 29, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Severe Sarcoidosis.

Vasileios Kouranos1, Joe Jacob2, Athol U Wells1

  • 1Interstitial Lung Disease Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.

Clinics in Chest Medicine
|November 24, 2015
PubMed
Summary

Identifying severe sarcoidosis is crucial for reducing mortality and preventing disability. This review highlights fibrotic lung disease and cardiac sarcoidosis as key concerns, suggesting a multidisciplinary staging approach for pulmonary disease.

Keywords:
Cardiac sarcoidosisPulmonary fibrosisSarcoidosis

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

948
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.4K

Related Experiment Videos

Last Updated: Mar 29, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

948
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.4K

Area of Science:

  • Pulmonology
  • Cardiology
  • Immunology

Background:

  • Sarcoidosis treatment aims to reduce mortality and prevent organ damage.
  • Identifying severe disease and at-risk patients is essential for effective management.
  • Fibrotic lung disease and cardiac sarcoidosis are primary causes of sarcoidosis morbidity and mortality.

Purpose of the Study:

  • To review the major contributors to sarcoidosis mortality and morbidity, specifically fibrotic lung disease and cardiac sarcoidosis.
  • To propose a multidisciplinary approach for staging severe pulmonary sarcoidosis in the absence of a standardized definition.

Main Methods:

  • Review of literature focusing on fibrotic lung disease and cardiac sarcoidosis in sarcoidosis.
  • Proposal of a clinical staging approach for pulmonary sarcoidosis.

Main Results:

  • Fibrotic lung disease and cardiac sarcoidosis are identified as the leading causes of death and disability in sarcoidosis patients.
  • A multidisciplinary staging approach, integrating clinical, functional, and imaging data, is suggested for pulmonary sarcoidosis.

Conclusions:

  • Early recognition and staging of severe sarcoidosis, particularly pulmonary and cardiac involvement, are critical for improving patient outcomes.
  • A comprehensive, multidisciplinary approach to clinical staging can aid in managing severe pulmonary sarcoidosis.